Abstract：
OBJECTIVE: Pediatric diffuse intrinsic pontine glioma (DIPG) is a fatal disease associated with a median survival of < 1 year despite aggressive treatments. This retrospective study analyzed the treatment outcomes of patients aged < 18 years who were diagnosed with DIPG between 2012 and 2022 and who received different chemotherapy regimens.
METHODS: After radiotherapy, patients with DIPG received nimotuzumab-vinorelbine combination or temozolomide-containing therapy. When nimotuzumab was unavailable, it was replaced by vincristine, etoposide, and carboplatin/cyclophosphamide (VECC). Temozolomide was administered as a single agent or a part of the combination chemotherapy comprising temozolomide, irinotecan, and bevacizumab. Furthermore, 1- and 3-year overall survival (OS), progression-free survival (PFS), and median OS and PFS were analyzed.
RESULTS: The median age of 40 patients with DIPG was 97 ± 46.93 (23-213) months; the median follow-up time was 12 months. One and 3-year OS were 35.0% and 7.5%, respectively. Median OS was 12 months in all patients (n = 40), and it was 16, 10, and 11 months in those who received first-line nimotuzumab-vinorelbine combination (n = 13), temozolomide-based (n = 14), and VECC (n = 6) chemotherapy regimens, respectively (p = 0.360). One patient who received gefitinib survived for 16 months. Conversely, patients who never received radiotherapy and any antineoplastic medicamentous therapy (n = 6) had a median OS of 4 months.
CONCLUSIONS: Nimotuzumab-vinorelbine combination therapy prolonged OS by 6 months compared with temozolomide-containing chemotherapy, although the difference was not statistically significant.
METHODS: After radiotherapy, patients with DIPG received nimotuzumab-vinorelbine combination or temozolomide-containing therapy. When nimotuzumab was unavailable, it was replaced by vincristine, etoposide, and carboplatin/cyclophosphamide (VECC). Temozolomide was administered as a single agent or a part of the combination chemotherapy comprising temozolomide, irinotecan, and bevacizumab. Furthermore, 1- and 3-year overall survival (OS), progression-free survival (PFS), and median OS and PFS were analyzed.
RESULTS: The median age of 40 patients with DIPG was 97 ± 46.93 (23-213) months; the median follow-up time was 12 months. One and 3-year OS were 35.0% and 7.5%, respectively. Median OS was 12 months in all patients (n = 40), and it was 16, 10, and 11 months in those who received first-line nimotuzumab-vinorelbine combination (n = 13), temozolomide-based (n = 14), and VECC (n = 6) chemotherapy regimens, respectively (p = 0.360). One patient who received gefitinib survived for 16 months. Conversely, patients who never received radiotherapy and any antineoplastic medicamentous therapy (n = 6) had a median OS of 4 months.
CONCLUSIONS: Nimotuzumab-vinorelbine combination therapy prolonged OS by 6 months compared with temozolomide-containing chemotherapy, although the difference was not statistically significant.
摘要：
目的：小儿弥漫性脑桥脑胶质瘤（DIPG）是一种致命性疾病，尽管积极治疗，但中位生存期<1年。这项回顾性研究分析了2012年至2022年间诊断为DIPG且接受不同化疗方案的年龄<18岁患者的治疗结果。
方法：放疗后，DIPG患者接受了尼妥珠单抗-长春瑞滨联合治疗或含有替莫唑胺的治疗.当尼妥珠单抗不可用时，被长春新碱取代,依托泊苷,和卡铂/环磷酰胺（VECC）。替莫唑胺作为单一药物或包括替莫唑胺的联合化疗的一部分给药，伊立替康,和贝伐单抗.此外，1年和3年总生存期（OS），无进展生存期（PFS），分析中位OS和PFS。
结果：40例DIPG患者的中位年龄为97±46.93（23-213）个月；中位随访时间为12个月。一年和三年OS分别为35.0%和7.5%，分别。所有患者的中位OS为12个月(n=40)，在接受一线尼妥珠单抗-长春瑞滨联合治疗的患者中，分别为16、10和11个月（n=13），替莫唑胺（n=14），和VECC（n=6）化疗方案，分别(p=0.360)。一名接受吉非替尼的患者存活16个月。相反，从未接受过放疗和任何抗肿瘤药物治疗的患者(n=6)的中位OS为4个月.
结论：尼妥珠单抗-长春瑞滨联合治疗与含有替莫唑胺的化疗相比，OS延长6个月，尽管差异无统计学意义。
方法：放疗后，DIPG患者接受了尼妥珠单抗-长春瑞滨联合治疗或含有替莫唑胺的治疗.当尼妥珠单抗不可用时，被长春新碱取代,依托泊苷,和卡铂/环磷酰胺（VECC）。替莫唑胺作为单一药物或包括替莫唑胺的联合化疗的一部分给药，伊立替康,和贝伐单抗.此外，1年和3年总生存期（OS），无进展生存期（PFS），分析中位OS和PFS。
结果：40例DIPG患者的中位年龄为97±46.93（23-213）个月；中位随访时间为12个月。一年和三年OS分别为35.0%和7.5%，分别。所有患者的中位OS为12个月(n=40)，在接受一线尼妥珠单抗-长春瑞滨联合治疗的患者中，分别为16、10和11个月（n=13），替莫唑胺（n=14），和VECC（n=6）化疗方案，分别(p=0.360)。一名接受吉非替尼的患者存活16个月。相反，从未接受过放疗和任何抗肿瘤药物治疗的患者(n=6)的中位OS为4个月.
结论：尼妥珠单抗-长春瑞滨联合治疗与含有替莫唑胺的化疗相比，OS延长6个月，尽管差异无统计学意义。
